Faeth Therapeutics (FTH) Current Assets (2020 - 2026)
Faeth Therapeutics' (FTH) quarterly Current Assets came in at $204.2 million in Q1 2026, up 472.37% YoY from $35.7 million in Q1 2025, and up 849.61% on a QoQ basis from $21.5 million in Q4 2025.
Faeth Therapeutics (FTH) Current Assets (2020 - 2026) Analysis & Trends
Faeth Therapeutics (FTH) has 7 years of Current Assets data on file, last reported at $204.2 million in Q1 2026.
- Quarterly Current Assets rose 472.37% year-over-year to $204.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $204.2 million (up 472.37% YoY) and the FY2025 annual result came in at $21.5 million, down 48.71% from the prior year.
- Current Assets climbed to $204.2 million in Q1 2026, from $21.5 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $204.2 million in Q1 2026 to a low of $21.5 million in Q4 2025.
- A 5-year average of $78.5 million and a median of $67.2 million in 2023 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2025 — Current Assets sank 48.71% — and 2026, when it surged 472.37%.
- Tracing FTH's Current Assets over 5 years: stood at $108.6 million in 2022, then tumbled by 38.07% to $67.2 million in 2023, then plunged by 37.65% to $41.9 million in 2024, then sank by 48.71% to $21.5 million in 2025, then soared by 849.61% to $204.2 million in 2026.
- The last three Current Assets figures came in at $204.2 million (Q1 2026), $21.5 million (Q4 2025), and $25.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Faeth Therapeutics | 179.31 Mn | 179.31 Mn | - | 188.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 188.66 Mn |
| Mar 31, 2026 | 204.23 Mn |
| Dec 31, 2025 | 21.51 Mn |
| Sep 30, 2025 | 25.79 Mn |
| Jun 30, 2025 | 29.57 Mn |
| Mar 31, 2025 | 35.68 Mn |
| Dec 31, 2024 | 41.93 Mn |
| Sep 30, 2024 | 48.10 Mn |
| Jun 30, 2024 | 53.94 Mn |
| Mar 31, 2024 | 60.23 Mn |
| Dec 31, 2023 | 67.25 Mn |
| Sep 30, 2023 | 73.84 Mn |
| Jun 30, 2023 | 81.07 Mn |
| Mar 31, 2023 | 98.61 Mn |
| Dec 31, 2022 | 108.59 Mn |
| Sep 30, 2022 | 118.48 Mn |
| Jun 30, 2022 | 127.49 Mn |
| Mar 31, 2022 | 138.98 Mn |
| Dec 31, 2021 | 148.54 Mn |
| Sep 30, 2021 | 158.16 Mn |